# Pediatric Arthritis Study of Certolizumab Pegol

> **NCT01550003** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 193 (actual)

## Conditions studied

- Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

## Interventions

- **DRUG:** Certolizumab Pegol (CZP)
- **DRUG:** Certolizumab Pegol (CZP)

## Key facts

- **NCT ID:** NCT01550003
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-08
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01550003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01550003, "Pediatric Arthritis Study of Certolizumab Pegol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01550003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*